DNA sequencing company Pacific Biosciences has reached a $600 million agreement to acquire Omniome, a startup with complementary sequencing technology. The cash and stock deal comes about 18 months after antitrust concerns led PacBio and sequencing giant Illumina to terminate their tie-up.
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation.
The $8 per share deal will allow Illumina to tap into the long-read sequencing market, while also heading off competition from other firms, analyst writes.
Samuel D. Waksal, the former chief executive of biotechnology company ImClone Systems who spent five years in federal prison for insider trading is mounting an audacious effort at redemption, again in biotechnology, the New York Times reports.
Highlights of the important and the interesting from the world of health care: What’s the most promising VC-backed health company? Of the 10,000 venture-backed private companies in the U.S., VentureSource has taken a stab at picking the Top 50 most promising ones. First some criteria: These private companies must have raised an equity round within […]